Anti-depressants and suicide

Jens Ludwig\textsuperscript{a, *},\textsuperscript{1}, Dave E. Marcotte\textsuperscript{b}, Karen Norberg\textsuperscript{c,1}

\textsuperscript{a} University of Chicago, 1155 East 60th Street, Chicago, IL 60637, United States
\textsuperscript{b} Department of Public Policy, University of Maryland Baltimore County, 100 Hilltop Circle, Baltimore, MD 21250, United States
\textsuperscript{c} Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, United States

\begin{abstract}
Suicide takes the lives of around a million people each year, most of whom suffer from depression. In recent years there has been growing controversy about whether one of the best-selling anti-depressants – selective serotonin reuptake inhibitors (SSRIs) – increases or decreases the risk of completed suicide. Randomized clinical trials are not informative in this application because of small samples and other problems. We present what we believe are the most scientifically credible estimates to date on how SSRIs affect suicide mortality using data from 26 countries for up to 25 years. We exploit just the variation in SSRIs sales that can be explained by institutional differences in how drugs are regulated, priced, and distributed, as reflected by the sales growth of new drugs more generally. We find an increase in SSRIs sales of 1 pill per capita (12% of 2000 sales levels) reduces suicide by 5%.
\end{abstract}

1. Introduction

Suicide claims the lives of about a million people around the world each year (Goldsmith et al., 2002) and currently ranks 11th among leading causes of death in the United States (National Vital Statistics Reports, 2007), yet economists have devoted surprisingly little attention to the topic. There is a very small theoretical literature that seeks to understand the nature of suicidal behavior (e.g., Hamermesh and Soss, 1974; Cutler et al., 2001; Becker and Posner, 2004). Even less attention has been devoted to the problem of suicide prevention, which has the potential to improve social welfare either by changing suicidal people’s desire for self harm, or by preventing them from acting on their desires.\textsuperscript{2}

This paper examines the effects on suicide from one of the most important, but increasingly controversial, tools for preventing suicide—modern anti-depressant drug treatment. Specifically, we provide what we believe to be the most scientifically credible estimate to date for the causal effects on suicide mortality from selective serotonin reuptake inhibitors (SSRIs). The SSRIs were introduced in the 1980s, and by 2000 were the most commonly prescribed drug class in the U.S. and the third best-selling drug class in the world (IMS Health, 2006). Yet SSRIs have been the subject of recent government safety warnings in the U.S. and U.K., which have led to large, widespread reductions in their use (Gibbons et al., 2007a) as well as sharp divergence in professional opinion about the safety of SSRIs. One researcher involved in the FDA’s reviews of SSRIs told the New York Times, “Sitting up there and having the public yell that you’re killing their children is no fun.” A medical historian told the Times “It’s like a religious war,” with a level of argument not seen since “the 1960s and 1970s, when scientists were challenging psychoanalysis” (Carey, 2006).

The expected net effect of the introduction and growing use of SSRIs on suicide mortality is ambiguous, \textit{a priori}. Anti-depressants may help people persevere through difficult but transitory periods of their lives. On the other hand, most anti-depressants appear to

\textsuperscript{*} Corresponding author. Tel.: +1 7738340811.
E-mail addresses: jiludwig@uchicago.edu (J. Ludwig), marcotte@umbc.edu (D.E. Marcotte), norberg@nber.org (K. Norberg).

\textsuperscript{1} National Bureau of Economic Research.

\textsuperscript{2} Some exceptions include Ludwig and Cook (2000), Duggan (2003) and Stevenson and Wolters (2006). One reason economists have worked little in this area is that the value of suicide prevention is ambiguous, since those at highest risk often suffer chronic health problems. This is one reason suicide rates are highest among the elderly (Goldsmith et al., 2002). But even here, treatment of depression and chronic pain can often increase the desire to live. One study found that among a sample of suicidal elderly people who had requested euthanasia, two-thirds changed their minds within two weeks (Hendin, 1999). This may or may not indicate that the desire to attempt suicide is fleeting, since even those with chronic or terminal health prob-

0167-6296/$ – see front matter © 2009 Elsevier B.V. All rights reserved.
improve patient energy levels before they improve mood, which may contribute to an increase in the risk of suicide during the early stages of treatment (FDA, 2006). There could also be what Viscusi (1984, 1985) terms a “nulling effect,” for example if medical practitioners react to the improved safety and reduced side effects of SSRIs relative to the older tri-cyclic anti-depressants (TCAs) by reducing the vigilance of supervision of potentially suicidal patients.

Concern about the safety of SSRIs has been motivated by several meta-analyses of randomized clinical trials (RCTs), which suggest that SSRI treatment elevates the risk for suicidal thoughts and non-lethal self-injurious behavior among pediatric patients and perhaps even adults as well. But the sample sizes used in these RCTs are too small to detect policy-relevant effects on suicide mortality. As a result, most RCTs rely on measures of non-lethal suicidality, which for reasons discussed further below are not very informative about drug impacts on mortality. Several non-experimental studies have compared trends in suicide and SSRI use across jurisdictions over time, a design that provides better statistical power than RCTs to detect impacts on suicide mortality, but raises concerns about the endogeneity of SSRI utilization rates. The magnitude and even the sign of the bias that may result are difficult to predict. Adverse changes in mental health may increase both SSRI sales and suicide, which would lead standard panel data analyses to underestimate any protective effects of SSRIs on suicide. But countries might also encourage SSRI use as part of a broader effort to improve mental health. Given the limitations of the existing empirical evidence, there remains great uncertainty about the public health effects of one of the world’s most widely used pharmaceutical products.

In this paper we present what we believe to be the first estimates for the effects of SSRIs on suicide using instrumental variables exogenous source of identifying variation and adequate statistical power to detect effects on mortality that are much smaller than anything that could be detected from randomized trials. We construct a panel dataset with suicide rates and SSRI sales per capita for 26 countries for up to 25 years. Since SSRI sales may be endogenous, we exploit institutional differences across countries that affect how they regulate, price, distribute and use prescription drugs in general (Berndt et al., 2007). Since we do not have direct measures for these institutional characteristics for all countries, we use data on drug diffusion rates as a proxy. We show that sales growth for SSRIs is strongly related to the rate of sales growth of the other major new drugs that were introduced in the 1980s for the treatment of non-psychiatric health conditions. This source of variation in SSRI sales helps overcome the problem of reverse causation and many of the most obvious omitted-variables concerns with past studies. Our research design may also have broader applications for the study of how other drug classes affect different health outcomes.

Our instrumental variables (IV) estimates suggest that an increase in SSRI sales of 1 pill per capita (around a 12% increase over 2000 sales levels) would reduce suicide mortality rates by around 5%. This relationship holds up even after conditioning on country and year fixed effects, country-specific linear trends, and many of the risk factors that previous research identifies for suicide (Goldsmith et al., 2002). Our estimates imply around 1 suicide is averted for every 200,000 pills sold.1 Our IV estimates are about twice as large as those from OLS, which is important because the magnitudes of impacts – not just their signs – matter for benefit–cost or cost-effectiveness analyses of health interventions. Commonly used SSRI can be obtained in the U.S. for around $0.11 per pill,4 which suggests a cost per statistical life saved from increasing SSRI use of around $22,000—far below most other government regulations or policies.

One drawback of country-level data is that SSRI sales information is not available for different population sub-groups, such as by age or gender. This limits our ability to identify heterogeneity in treatment effects, which could in principle be valuable for helping health policymakers target SSRI use within the population. However, the degree to which regulators can in fact influence SSRI use in targeted ways remains unclear. For example, SSRIs were widely used for “off-label” treatment of depression among adolescents and children prior to FDA approval (Olsson et al., 2002a,b, and Zito et al., 2003).5 After the FDA issued a warning in 2004 about SSRI use in pediatric patients, SSRI sales declined among almost all adult age groups as well (Gibbons et al., 2007a). Given this broad-based response to age-targeted warnings, the question we address here seems relevant to a broad range of policy decisions.

The most important concern with our estimates comes from the fact that our instruments are not randomly assigned across countries, and so there is necessarily the question of whether they are orthogonal to other determinants of suicide. A variety of specification tests provide some support for our research design. One specific concern is that prescription drugs may diffuse more rapidly in higher-income countries (Slade and Anderson, 2001). However, we show that our results are not affected when we control for economic conditions. A related concern is that new drugs may diffuse more quickly in countries that are more intensive users of medical care overall, so that our IV estimates might be picking up effects that more or better health care may have in reducing the prevalence of (or pain associated with) chronic health problems that lead some people to contemplate suicide. But we find that the rate at which new drugs diffuse is unrelated to the trend in health spending in our sample. Countries that have made similar policy decisions about how to operate their general health care systems have made different choices about how to regulate, price or distribute prescription drugs. We also show there is no estimated SSRI “effect” on accident mortality, and that predicted SSRI sales are most strongly associated with declines in suicide mortality among teenagers and young adults, rather than among older age groups for which chronic health problems or pain are most common. As a more general specification test, we compare countries that our design predicts to have faster versus slower rates of growth in SSRI sales, and show they have similar “pre-treatment” trends in suicide mortality in the period before SSRIs are introduced. One might still worry that the use of other mental health treatments may have increased over the 1990s during the time when SSRI sales were increasing rapidly, but among the set of countries for which we can obtain data we find no increases in psychotherapy or use of older TCA anti-depressants during the 1990s.

The next section discusses the pathways through which anti-depressant drugs could affect suicide, while Section 3 reviews available evidence on this question. We discuss our data in Section 4 and empirical methods in Section 5. The main findings are in Section 6, while implications are discussed in Section 7.

---

1 In Table 1 below we show that the mean suicide rate for our sample over the study period is about 10 per 100,000. Our point estimate thus implies that an increase in SSRI sales of 1 pill per capita reduces suicide mortality by 5%([10/100,000]) = 0.00005 deaths per capita. So an increase in SSRI sales of 200,000 pills would reduce mortality by 1 statistical life.

4 Many retailers, including Walmart, offer 90 pills of generic SSRIs for $10, or about $0.11 per pill.

5 Fluoxetine (Prozac) is the only SSRI ever approved for treatment of children and adolescents, but off-label pediatric use of SSRIs is so wide spread that the FDA black-box warning on suicide for adolescents included other SSRIs, as well.
2. Background

Many people are at elevated risk for suicide because of major depressive disorder, which affects between 30 and 90% of those who complete suicide (Goldsmith et al., 2002, p. 70) and around 17% of all American adults at some point over their lifetimes (Kessler et al., 2005a). Since major depression is a leading risk factor for suicide, it might be expected that the use of anti-depressant drugs would reduce suicide. Yet concern that anti-depressant drugs could increase, rather than decrease, the risk of suicide dates back to the 1950s with the introduction of the tri-cyclic anti-depressants (TCAs). TCAs might increase the risk of suicide partly because of their slow therapeutic effects. Most anti-depressants (including SSRIs and TCAs) take four or more weeks to result in a clinically significant improvement in depressed mood, but other psychopharmacological effects, such as increased energy levels, may occur within the first few days of treatment. As early as the 1960s, psychiatry textbooks warned the risk of suicide may increase during early phases of treatment because the medications may give suicidal patients the energy to follow through on a suicidal motive, long before they led to improved mood. A second clinical concern about the effects of TCAs on suicide stems from the possibility that drug effects might differ across patients of different ages.6

A different type of behavioral mechanism through which the introduction of TCAs might have increased suicide risk stems from the fact that the TCAs were highly toxic in overdose, so that a prescription might provide easy access to an effective method of self harm. If suicide methods are not perfectly substitutable, and if people at high risk for suicide are at least somewhat responsive to the availability of different methods, then easier access to a preferred method of suicide might influence the “costs of death” (Hamermesh and Soss, 1974; Becker and Posner, 2004). And finally, anti-depressant drug treatment could increase the risk of suicide if forward-looking suicidal people sometimes choose to wait to attempt suicide to see if their life conditions improve (Becker and Posner, 2004). People hoping that drug therapy may improve their lives could interpret the lack of mood improvement during the early stages of treatment as indication that they will never respond to treatment, and so give up hope that their lives will ever improve.

A major technological innovation in the treatment of depression occurred in 1984 with the introduction of selective serotonin reuptake inhibitors (SSRIs). SSRIs are “selective” because they affect only the reuptake pumps responsible for serotonin, a small molecule that serves as a neurotransmitter, or “chemical messenger,” in the brain. While the SSRIs appear to be similar to TCAs in their ability to reduce depression,7 they are more selective in their operation and therefore have fewer physical side effects (such as dry mouth, drowsiness, or cardiac arrhythmia). The introduction of SSRIs may have reduced suicide in two ways. First, SSRIs are less toxic in overdose compared to TCAs.8 Second, the greater safety of SSRIs has probably led anti-depressants to be prescribed for more patients by a wider range of practitioners (Guze, 1996; Lawrenson et al., 2000).10

However there are also mechanisms through which SSRIs could increase the risk of suicide, compared to the risks when TCAs were the primary treatment available. One possibility is that adverse or “paradoxical” effects on mood could differ across drugs. It is also possible that SSRIs could increase suicide risk through a “lulling effect” (Peltzman, 1975; Viscusi, 1984, 1985). The greater safety of SSRIs relative to TCAs may have led a broader (and perhaps less experienced or qualified) set of practitioners to be willing to provide drug treatment for depression,11 and may also have led payers, clinicians, and patients to accept a shortening of in-patient hospital stays and reduction of intensity of outpatient treatment.12 The introduction of safer SSRIs could also increase the number of unintentional deaths resulting from self-injury attempts without lethal intent, for example from suicide attempts that are motivated primarily by the desire to signal for help or punish family or friends (Rosenthal, 1993; Cutler et al., 2001; Marcotte, 2005).

3. Previous evidence on SSRIs and suicide risk

The question of whether anti-depressant drugs might increase suicide risk first came to national attention in 1990, with the publication of a case study of six adults who became suicidal after being treated with Prozac (Teicher et al., 1990). Most of the subsequent public attention has focused on evidence from RCTs, although any feasible trial or even pooled set of trials will have sample sizes that are too small to detect policy-relevant impacts on suicide mortality. For example, to detect an effect on suicide mortality of 20%, a randomized trial would need 1.9 million subjects (Gunnell et al., 2005). But increases in suicide risk of much less than 20% would still be of great importance for both drug regulators and clinical practitioners. To detect an impact of, say, 5%, a trial would need to enroll around 30 million patients—about twice the number of people in the U.S. who suffer from major depressive disorder in any given year.

Most RCT studies have focused instead on measures of non-lethal “suicidality.” For example, the FDA’s 2003 review of pediatric trials found that among 4400 patients age 18 or younger, SSRI use was estimated to double the risk of suicide-related behaviors or ideation versus placebo (4% versus 2%). It is worth noting the pooled set of trials did not include any completed suicides (Hammad et al., 2006). A more recent meta-analysis of pediatric trials also finds an elevated risk for suicide ideation or attempts for SSRI versus placebo for patients with major depressive disorder (3% versus 2%; N = 2910, p = .08), with smaller risk differentials.

---

6 As pharmacological treatments become more accepted, they are often adopted for use in pediatric practice, but there has been ongoing concern that medica- tions developed and tested in adults might have different effects in children, and adolescents.

7 Suicide methods may not be perfect substitutes in part because of considerable variability in skill required, physical pain, likelihood of rescue, likelihood of a fatal outcome, and likelihood of permanent injury if the outcome is not fatal. Previous research provides at least qualified support for the idea that changing access to suicide methods may achieve at least temporary reductions in suicide (Kessler 1976; Ludwig and Cook, 2000; Goldsmith et al., 2002; Duggan, 2003).

8 See Trindade et al. (1998), Goldsmith et al. (2002), Mallick et al. (2003), Ryan (2003), Green (2003), and Vaswani et al. (2003).

9 The improved ratio of a therapeutic dose to a toxic dose of SSRIs means that an act of intentional self harm by swallowing, say, a one-month supply of SSRIs is probably less lethal than swallowing a one-month supply of TCAs. Little is known about the case fatality rates for overdoses with SSRIs versus TCAs, or whether patients are aware of the relative toxicity of the two medications.

10 Some of the increase in SSRI use could have been substitution from talk therapy, and current research is ambiguous about the relative effectiveness of the two forms of treatment (e.g., Klein, 2000), but overall, SSRIs have probably contributed to a net increase in the number of people being treated for depression in the U.S. (Kessler et al., 2005b; Thorpe et al., 2004).

11 In many countries there have been dramatic shifts from providing psychiatric services in state psychiatric hospitals to treatment in community settings, which is thought to have been prompted in part by the development of safer and more effective drug treatment. But there is also a long history of concern that deinstitutionalization may have led to a higher suicide rate (e.g., Hansen et al., 2001; Flechner et al., 1995; Salzer et al., 2006) for much the same reasons that improved product safety could increase the risk of product injury rates if consumers (or clinicians or policy makers) have misconceived the actual risks.

12 Many studies find a combination of drugs and psychotherapy is more effective than either alone (e.g., March et al., 2004), so SSRIs might increase the risk of sui- cide among those who would have been referred for more intensive treatment and supervision.
for pediatric patients with obsessive-compulsive or other anxiety disorders (Bridge et al., 2007).

Recent meta-analyses of RCTs suggest that SSRI s may increase the risk of suicidal thoughts and behavior among adults as well. Fergusson et al. (2005) find a positive and statistically significant increase in suicide attempts for those treated with SSRIs compared to placebo (odds ratio = 2.28, 95% CI 1.14–4.55, N = 36,445), with odds ratios above 1 for all adult age groups except adults over age 60. The meta-analysis of Gunnell et al. (2005) yields similar findings for non-lethal self-harm attempts, although the estimate is not quite statistically significant (odds ratio = 1.57, 95% CI 0.99–2.55), even with 45,704 patients. The FDA’s own 2006 review of RCTs with a total of 99,839 adult patients yields qualitatively similar findings: Compared to placebo, SSRIs may reduce the risk of suicide ideation (odds ratio = 0.86, 95% CI 0.69–1.06), but may increase the risk for suicide preparation or worse (odds ratio = 1.23, 95% CI 0.82–1.85). For suicide preparation, the FDA estimates separate odds ratios by age that are greater than 1 for all adult age groups below age 65, although these age-specific results do not distinguish SSRIs from other anti-depressants.

Unfortunately the available measures of non-lethal suicidal ity that have been used in these trials suffer from a number of important limitations. Only a small fraction of patients with suicidal thoughts attempt suicide, few attempts are fatal, and the risk factors for suicide attempts are different from the risk factors for completions (Cutler et al., 2001; Baldessarini et al., 2006). These measures are also retrospectively derived from patient records, and so are susceptible to “ascertainment bias”—compared to placebo, treatment with any active drug will entail more side effects, and so will generate more doctor visits (Gibbons et al., 2007a). Similarly, suicide attempts based on overdose of study medication result in more contact with the health care system for those assigned to the treatment rather than placebo group. Classification of these nonfatal suicide reports is not straightforward (Posner et al., 2007). And RCTs suffer problems of external validity as well, since they exclude people at highest risk for suicide, and treatment in RCTs may be unrepresentative of usual community levels of care.

Given the limitations of RCTs, numerous investigators have used non-experimental research designs to examine the association between SSRIs and suicide mortality. However, most previous population-based studies have used research designs with limited power to rule out the influence of competing explanations. For example, several studies have used interrupted time series designs, comparing suicide rates before and after SSRIs become available in a particular jurisdiction, which yield conflicting results (Isacsson et al., 2000; Rihmer et al., 2001; Ohberg et al., 1998; Hall et al., 2003, versus Helgason and Zoga, 2004; Barbui et al., 1999). 15

Two studies have improved on this before/after design by relating variation in SSRI sales across jurisdictions over time within a given country. Using data for the U.S. from 1996 to 1998; Gibbons et al. (2005, 2006) find that increases in prescriptions for SSRIs and other newer anti-depressants are associated with lower suicide rates both within and between counties, including for children and adolescents. 16 Dahlberg and Lundin (2005) examine variation in SSRI sales across counties and age groups in Sweden, and find no significant association between SSRI sales and suicide rates. A third study using this same basic approach examines variation in use of SSRIs across countries, over time. Ludwig and Marcotte (2005) use data from 27 countries over 20 years, and condition on country-specific linear trends as well as country and year fixed effects. An increase in SSRI sales of one pill per capita is associated with a 2.5% decline in suicide.

The main concern with panel data studies is that they may still be susceptible to bias from other unmeasured factors that affect both changes in SSRI use and suicide mortality. The magnitude, and even sign, of bias is hard to predict. The most obvious concern is that adverse changes in population mental health may increase both SSRI sales and suicide, which would lead standard panel data methods to understestate any protective effects of SSRIs on suicide. For example, Japan normally approves new drugs for sale within a year or two after they are introduced anywhere else on the world market. But Japan approved SSRIs for sale around 15 years after they were introduced, and then only in response to a massive increase in suicide during the 1990s. 17 The Japanese case also highlights the possibility of bias in the opposite direction: Japan’s approval of SSRIs for sale came during a period of growing public awareness and corporate and government response to mental and public health problems, including efforts to combat karoshi, or death from over-work, and group suicide pacts among young people.

The main contribution of our paper is to try to overcome this endogeneity problem by using a plausibly exogenous source of identifying variation in SSRI sales, together with population-level data that provide adequate power to detect impacts on suicide mortality. Specifically, we use just the variation in SSRI sales that can be predicted from the rate of growth in sales of the major nonpsychiatric medications that were introduced over the same time period (the 1980s) in which SSRIs were introduced, which we take as a proxy for differences across countries in institutional features that affect the pricing, regulation, distribution and use of drugs in general. Our research design assumes that these institutional differences across countries in drug markets overall are unrelated to differences in trends across countries in mental health problems or treatment. Below we discuss this assumption in detail and present tests of the plausibility of our identifying assumption.

### 4. Data

Annual data on suicide mortality is available for a large sample of countries from the World Health Organization (WHO), which come from national vital statistics systems. These data include the annual number of total suicides and by gender and age, as well as relevant population counts. We have these data for 1980–1999 for all countries in our sample, and have been able to extend the panel through at least 2000 for about half our sample. 18 There may

---

13 Some evidence to support this concern comes from the fact that the ratio of non-fatal to fatal suicide attempts is often much higher for treatment groups assigned to SSRI medication compared to placebo control groups. For example in the meta-analysis of Fergusson et al. (2005), the ratio of non-fatal to fatal attempts is 5.75 to 1 for the treatment group and 2 to 1 for placebo controls.

14 See for example Pearson et al. (2001), Goldsmith et al. (2002), Zimmerman et al. (2002), Baldessarini (2005), Fergusson et al. (2005), Baldessarini et al. (2006), and Khan et al. (2000, 2006).

15 A different approach adopted by Jurgil et al. (2006) is to use individual-level data from medical records and compare suicide rates for those who receive SSRI treatment versus others, using propensity-score matching methods to control for selection into SSRI treatment on the basis of observable background characteristics. Gibbons et al. (2007b) employ a difference-in-differences design with individual-level patient data from the VA, comparing trends in suicide attempt rates for those diagnosed with depression who do versus do not receive drug treatment.

16 Their study uses a multi-level mixed-effects Poisson regression that allows for heterogeneity across counties in the relationship between SSRI prescription rates and suicide mortality rates.

17 Previous research from the US also suggests that more important drugs that address more high-visibility health problems seem to be approved by the FDA more quickly (Kaitin et al., 1991; Dranove and Meltzer, 1994; Carpenter, 2002).

18 Most of these suicide reports were recorded by local medical or public health officials using the International Classification of Diseases, 9th Revision (ICD-9) system for coding cause of death, although by the end of the panel some countries use the ICD-10. While data from the United States suggests that both coding schemes...
be some differences across countries in the ability or willingness of medical officials to determine and report mortality events as suicides, and vital statistics systems in developing countries are in particular thought to be problematic (Goldsmith et al., 2002, p. 212–213). Improvements in suicide recording practices common to all countries will be captured by the time effects included in our model, while stable country-specific differences in recording practices will be accounted for by country fixed effects, and the inclusion of country-specific linear trends in our models should help account for gradual country-specific changes in data quality. Unless any remaining measurement error in these suicide data is systematically related to our instruments, problems with the suicide data should simply reduce the precision of our estimates.

The main constraint on the construction of our country-level sample is the availability of data on SSRI sales. Our core analytic sample consists of the 26 countries for which we have been able to obtain annual SSRI sales data from IMS Health, Inc., a commercial firm that provides data on international pharmaceutical sales to manufacturers and health care providers. The diverse set of countries in our main analytic sample (with their year of first SSRI sale in parentheses) are: Argentina (1989); Australia (1990); Austria (1985); Belgium (1985); Brazil (1989); Canada (1989); Chile (1989); Colombia (1990); Ecuador (1991); Finland (1989); France (1986); Greece (1990); Ireland (1989); Israel (1989); Italy (1988); Japan (1999); Luxembourg (1985); Mexico (1989); Netherlands (1985); New Zealand (1988); Norway (1996); Portugal (1986); Spain (1987); United Kingdom (1987); United States (1988); and Venezuela (1990). One possible concern is that our sample of countries is too diverse, although we demonstrate below that our results are similar when we restrict attention to just member nations of the OECD, which should also have more similar data practices.19, 20

For each of these countries we have information about drug approval dates back to 1980 for all SSRIs, which includes fluoxetine, paroxetine, fluoxetine, sertraline, citalopram and venlafaxine. We have also been able to obtain data on actual SSRI sales for these countries for each year back to 1990. The fact that we do not have SSRI sales data before 1990 could in principle complicate our analysis, although it is important to note that most countries began to sell SSRIs starting only in the late 1980s, and in almost all countries, SSRI sales growth was a phenomenon of the 1990s (see Table 1). For countries that approved SSRIs before 1990, we know what sales were in the years before approval – zero. We use linear interpolation to impute sales in years between the date of SSRI approval and 1990.21 More complicated imputation procedures are possible, but it turns out that our results are not sensitive to how we address this problem.

capture suicides in a consistent fashion (Anderson et al., 2001), in our analysis we accounted for the possibility that this shift could change recorded suicide rates within our sample. 19 This restriction drops Argentina, Brazil, Chile, Colombia, Ecuador, Israel, and Venezuela.

20 We exclude countries that transitioned from communist to other forms of government during our sample period (including Germany) in part because of limited availability of data on drug sales and in some cases for suicides during the pretransition period. We also wish to avoid confounding the introduction of SSRIs with the profound social changes that accompanied these transitions (see for example Webb et al., 2005 for a discussion of the Ukraine). For Germany the challenge is that we cannot obtain annual suicide mortality data for East Germany prior to 1998; in that year suicide rates per 100,000 are more than 1.5 times as high in East versus West Germany (25.8 versus 16.5). Using data just on West Germany over our study period is problematic in part because of increased migration of East Germans into the West following reunification.

21 Specifically for each country we know sales in the year before approval (zero) and from our data sales levels in 1990, and then just linearly interpolate SSRI sales data in the intervening years.

### Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Description</th>
<th>Mean</th>
<th>Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suicide rates per 100,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>10.1419</td>
<td>5.9292</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>15.4149</td>
<td>8.5891</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>5.1935</td>
<td>5.1935</td>
</tr>
<tr>
<td>Age 15–24</td>
<td></td>
<td>8.2268</td>
<td>4.0046</td>
</tr>
<tr>
<td>Age 25–34</td>
<td></td>
<td>11.1920</td>
<td>5.5708</td>
</tr>
<tr>
<td>Age 35–44</td>
<td></td>
<td>12.2534</td>
<td>6.8066</td>
</tr>
<tr>
<td>Age 45–54</td>
<td></td>
<td>14.1380</td>
<td>8.7442</td>
</tr>
<tr>
<td>Age 55–64</td>
<td></td>
<td>14.5407</td>
<td>8.9454</td>
</tr>
<tr>
<td>Age 65 and over</td>
<td></td>
<td>18.5482</td>
<td>11.9183</td>
</tr>
<tr>
<td>% Population in age group:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15–24</td>
<td></td>
<td>16.4555</td>
<td>2.9794</td>
</tr>
<tr>
<td>25–34</td>
<td></td>
<td>15.4560</td>
<td>1.3395</td>
</tr>
<tr>
<td>35–44</td>
<td></td>
<td>13.2939</td>
<td>1.9874</td>
</tr>
<tr>
<td>45–54</td>
<td></td>
<td>10.5985</td>
<td>2.4970</td>
</tr>
<tr>
<td>55–64</td>
<td></td>
<td>8.4401</td>
<td>2.5647</td>
</tr>
<tr>
<td>65 and over</td>
<td></td>
<td>10.5681</td>
<td>4.3550</td>
</tr>
<tr>
<td>Real GDP per capita*</td>
<td></td>
<td>16.747</td>
<td>8.118</td>
</tr>
<tr>
<td>Unemployment rate</td>
<td></td>
<td>7.1428</td>
<td>3.8937</td>
</tr>
</tbody>
</table>

**Suicide data coded using ICD10**

1990

<table>
<thead>
<tr>
<th>Year</th>
<th>Suicides per 100,000</th>
<th>SSRI doses capita</th>
</tr>
</thead>
<tbody>
<tr>
<td>1980</td>
<td>9.3718</td>
<td>5.9366</td>
</tr>
<tr>
<td>1985</td>
<td>10.3165</td>
<td>6.5327</td>
</tr>
<tr>
<td>1990</td>
<td>9.7190</td>
<td>5.7663</td>
</tr>
<tr>
<td>1995</td>
<td>9.1212</td>
<td>5.5527</td>
</tr>
<tr>
<td>2000</td>
<td>9.617</td>
<td>6.4063</td>
</tr>
<tr>
<td>2005</td>
<td>5.6454</td>
<td>5.4700</td>
</tr>
</tbody>
</table>

Notes: Authors’ calculations from WHO mortality and SSRI sales data for sample countries (see text). Calculations are weighted by country population.

* GDP per capita adjusted for changes over time across countries in currency exchange rates.

In our analyses we also controlled for a number of factors identified by a recent IOM report as risk factors for suicide (Goldsmith et al., 2002). For example there is a powerful age structure to suicide mortality (Table 1), and so we control for the annual distribution of each country’s population across different age groups. We also have data on unemployment rates from the OECD, data on real per capita gross domestic product adjusted for changes over time in exchange rates (World Bank, 2006), health care expenditures per capita for a subset of OECD countries, and divorce rates.

### 5. Empirical strategy

In this section we begin by outlining a basic OLS approach that provides a benchmark for estimates that come from our preferred IV design, which is then discussed in detail in the second sub-section below.
5.1. Least squares setup

We begin by estimating Eq. (1) using population-weighted least squares,22 where $Y_{it}$ is equal to the natural log of country $i$’s suicide rate per 100,000 in year $t$, and $SSRI_{it}$ is the number of SSRI pills sold per capita in country $i$ in year $t$. We control for the share of the population in different age groups (15–24, 25–34, 35–44, 45–54, 55–64, and 65+), an indicator for whether the country records deaths in that year using the ICD-10 versus -9 system, country and year fixed effects $d_i$ and $d_t$ and country-specific time trends, $Time_t \times d_i$. To account for serial correlation, we cluster standard errors at the country level (Bertand et al., 2004).23

$$Y_{it} = a_0 + a_1 SSRI_{it} + a_2 X_{it} + d_i + d_t + (Time_t \times d_i) + \epsilon_{it}$$

(1)

Most of the variation in suicide mortality rates in our panel is across countries rather than over time: country fixed effects account for about four-fifths of the total variation in log suicide rates. For example, the suicide rate in 1990 per 100,000 people was 3.4 in Greece, 12.4 in the U.S. and 23.3 in Austria. These differences in suicide rates across countries are thought to be due to in part to climate, culture, urbanity, and perhaps data recording practices (Smith et al., 1995; Goldsmith et al., 2002, Chapter 6). The substantial cross-sectional variation in suicide mortality suggests that a proportional response model is more appropriate than one focused on impacts measured in levels. Our preferred model takes a log-linear form, although our results are generally not overly sensitive to functional form decisions. Country and year fixed effects plus country-specific linear trends account for 90% of the variation in log suicide rates in our panel.

5.2. Instrumental variables design

The main concern with OLS estimates of Eq. (1) is that SSRI sales may be endogenous to the conditions that influence suicide. For example, increases in major depressive disorder could drive up SSRI sales. Since reliable longitudinal, population-level estimates for the prevalence of severe depressive disorder are not available, even in our sample of developed countries, OLS estimates may underestimate in absolute value any beneficial effect of SSRIs on suicide. On the other hand, countries might expedite approval of SSRIs or implement policies designed to improve access to SSRIs as part of a larger portfolio of efforts designed to improve mental health, in which case OLS would overstate the protective effects of SSRIs on suicide.

Our preferred research design seeks to identify the effect of SSRIs on overall suicide mortality using just the variation in SSRI sales across countries over time that can be explained by differences across countries in how quickly new drugs are generally approved,24 and the general rate at which sales of new drugs usually increase once they are approved for sale on the market. The first source of variation turns out to not be very relevant for our design, since most countries in our panel are fairly rapid adopters of new drugs in general. Our IV estimates are thus driven mostly by variation across countries in the rate at which new drugs diffuse over time, and the validity of our estimates depends on whether rates of diffusion of new drug technologies are indeed orthogonal to other determinants of suicide mortality across countries. We argue below that this assumption seems plausible, and present some empirical results to support this view.25

Conceptually, our IV design takes advantage of the fact that there are institutional differences in the drug regulation, distribution and demand systems across countries that are common to both SSRIs and to other drugs. Data on the sales trajectories of other drugs that are not used to treat psychiatric conditions can tell us something about what combined the simultaneous adoption of new drugs and drug diffusion rates. These general drug diffusion tendencies for countries should not be affected by the level or trend in mental health conditions, which is one of the main threats to validity with OLS.

Importantly, the institutional features that influence drug diffusion within countries seem to be large part independent of other aspects of the country’s health care system. Countries that have made generally similar policy decisions about how to structure their overall health care systems differ in how they choose to regulate, subsidize, or distribute drugs. Berndt et al. (2007) examine data from 15 countries, most of which are included in our own analytic sample, and find that the rate of sales growth for new drugs is unrelated to the country’s type of health care system—that is, whether health care costs are supported by a tax-funded system, by a social insurance-based system, or by a mixed system. Below we show that predicted rates of SSRI sales growth are unrelated to trends in health care expenditures across our sample of countries. Consider, for example, the cases of Australia, Canada, and the UK, which all provide universal health care coverage funded in large part by general tax revenues, rely mostly on public hospitals, and use physicians as gatekeepers for the system who are then reimbursed on a fee-for-service basis (at least in Australia and Canada; physician reimbursement is more complex in Britain; see Commonwealth Fund, 2005). Yet these three countries have

22 We use population-weighted least squares, since our suicide mortality rates are essentially grouped data and the ratio of signal to noise seems to be much higher for more populous countries. A Breusch-Pagan test confirms OLS residuals from estimating Eq. (1) vary substantially by country size. As we show below, the point estimates from our unweighted regressions are similar to the weighted results but less precisely estimated—as we would expect from an estimate that gives the same weight to noisy suicide data from small countries, like Luxembourg, that is given to observations from larger countries, like the U.S. For example the suicide rate per 100,000 in the U.S. changes modestly year to year (from 1980 to 1985 the annual rate was equal to 11.9, 12.0, 12.2, 12.1, 12.4, 12.6). The year-to-year variability is much larger in Luxembourg (12.8, 16.7, 21.3, 21.9, 18.6, and 14.8).

23 The raw data suggested that these country-specific linear terms may be important given differences in trends even before SSRI use became widespread. For example, in Austria the suicide rate declined from 25.4 per 100,000 in 1980 to 23.3 by 1990 and 18.1 by 2001. In contrast, the suicide rate in Mexico increased steadily from 1.4 per 100,000 in 1980 to 3.8 by 2001. The rise in suicide rates over the panel for Mexico may reflect a change in reporting, rather than real patterns of mortality, due to a declining stigma associated with suicide. Other predominantly Catholic countries (Ireland, Spain, Italy) saw similar patterns.

24 Hansen (2006) shows that standard errors calculated in this way may be overly conservative.

25 There are many cultural and institutional reasons why drug approval times might vary across countries. To take just one example, the U.S. Prescription Drug User Fee Acts (PDUFA) was intended to provide additional resources to FDA to speed up drug approvals by charging drug companies user fees. User fees from drug companies vary considerably—for example the United Kingdom’s Medicine and Healthcare Products Regulatory Agency receives 100% of funding from user fees, while Japan’s Koseiho regulatory agency does not charge any user fees (Berndt et al., 2005). Sociological factors may also influence patterns of technology adoption. For example, Skinner and Stagner (2005) found that some states in the US consistently adopted effective new technologies, whether hybrid corn, tractors, or heart attack treatments, earlier than other states. They also found that early adoption was closely associated with social capital and state-level 1928 high school graduation rates, but not per capita income, density, or (in the case of Beta Blockers) expenditures on heart attack patients.

26 It is also worth noting that unknown to us when we started this research, one other study has used an identification strategy that relies on differential rates of drug diffusion across areas to examine the effects of a different class of drugs (antipsychotics) from the one examined here. In that case the non-experimental findings were later validated by a subsequentRCT. Specifically, Duggan (2005) uses variation across areas of California in drug diffusion to show that second-generation antipsychotic drugs do not not reduce health care spending. A similar finding was produced by a subsequent randomized clinical trial involving 1493 patients (Rosenheck et al., 2006).
different systems for handling prescription drugs. The Australian government subsidizes most drug purchases in the country and accounts for the majority of all expenditures on drugs, but these subsidies are limited to drugs that are listed in a “positive formula- ary” (Morgan et al., 2006). Drugs not included on this list receive very little use. The Australian government negotiates the prices for drugs on this list with pharmaceutical companies. In the UK, drugs are provided through the National Health System, with a “negative formulary” (a list of drugs excluded from the NHS subsidy) and a fixed charge to patients per prescription. During our study period, the UK had some regional variation in drug coverage (Morgan et al., 2006). In the UK, unlike Australia, the government does not negotiate drug prices, but instead regulates profits for drug companies for on-patient drugs, and allows free pricing for off-patient drugs (Kanavos, 2006). This relatively greater pricing flexibility for companies in the UK leads generics to be relatively more common in that country, which, incidentally, they also are in the US (Konigbauer, 2007). The Canadian government funds only around half of all drug purchases, subsidies that are provided through a mixture of federal and local drug plans that all have their own positive formularies. But supplemental private insurance to help cover outpatient drug costs is widespread (Watson Wyatt Insider, 2007). And, as our results below demonstrate, there are indeed important differences across these three countries in sales growth of new drugs.

While systematic research on the role of specific drug sector characteristics in explaining drug diffusion rates is limited, existing studies provide at least a few clues. Berndt et al. (2007) show that there is important variation across countries in how new drugs are priced, and this variation in new drug prices influences the rate at which new drugs diffuse. Berndt and colleagues also find that the degree to which drug companies promote new drugs matters—there is a positive relationship between new drug diffusion and the number of contacts between drug representatives and doctors (“details”). Chintagunta and Desiraju (2005) study a sample of five countries, four of which are in our analytic sample. Among these four countries they find that the frequency of detailing for SSRIs is highest in the US, followed by France, then the UK, then Italy. As shown below, this is also exactly the ranking of these countries in the rate at which our instrument predicts SSRI sales to grow over time. Another factor that may influence drug diffusion rates across countries comes from the strategic business decisions made by pharmaceutical companies in different countries. For example, Chintagunta and Desiraju find some evidence that there is a “home bias” in the behavior of pharmaceutical companies, which behave more aggressively towards competitors in the drug markets within the country where the company is based. In the US we have seen that a change to the way pharmaceuticals are financed for the elderly in the US (in the form of a new 2006 Medicare drug benefit) increased retail spending on prescription drugs by 8.5% in its first year (Pear, 2008).

Since data on the specific institutional features of each country’s pharmaceutical regulation and distribution are not available for many countries at many different points in time, we try to instead capture these institutional differences by looking at variation in how other new drugs generally diffuse across countries. This approach raises the question of which new drugs we should use to construct our instruments. We obtained data from IMS Health about drug introduction dates and sales for those drug classes that satisfied three criteria: (1) Like SSRIs, they must have been introduced in the 1980s, so that the set of institutions that generally affect the drug adoption process are similar across drug types; (2) Unlike SSRIs, these drugs should not be used in the treatment of psychiatric illnesses, to avoid the potential endogeneity problems described above; (3) Like SSRIs, they must have been among the top-ten selling drug classes at the end of our study period (1998–2000), in the event that there is some general “major drug” effect on regulatory approval or sales trends. The drug classes that satisfy these three criteria are summarized in Table 2: Statins, a class of drugs designed to lower LDL (“bad”) cholesterol; proton pump inhibitors (PPIs), which are used to treat stomach and duodenal ulcers; and two drug classes used to treat hypertension, calcium channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. Together with SSRIs, the drugs included in our instrument set accounted for 83% of the sales of the top 10 drugs sold in the U.S. in 1998 (Kreling et al., 2000) and account for four of the five top selling drug classes (BarentsGroup, 1999).

Mechanically, our IV design works as follows. We begin with a just-identified IV setup given by:

\[ Y_d = b_0 + b_1\text{SSRI}_d + b_2\text{X}_{d1} + d_i + \text{Time}_t \ast d_i + v_{t}\text{it} \quad (2) \]

\[ \text{SSRI}_d = c_0 + c_1\text{PSALES}_{d1} + c_2\text{X}_{d1} + d_i + \text{Time}_t \ast d_i + v_{t}\text{it} \quad (3) \]

Our instrument, PSALES, equals the SSRI sales level that we predict for country \( i \) in year \( t \) if the country had approved SSRIs as quickly as the country approved the four major non-psychiatric drug classes that were introduced in the 1980s (Statins, PPIs, CCBs, and ACE inhibitors), and then if SSRI sales grew each year they are on the market at the same rate as these other drugs. Put differently, our instruments represent the counterfactual SSRI sales pattern we would have expected in these countries if SSRI sales followed the same introduction and sales patterns observed for other major new drugs. We argue that this variation in SSRI sales is driven by institutional factors that are largely specific to each country’s pharmaceutical system. To construct this instrument we first calculate the predicted SSRI adoption lag for each country (\( P_{Lag} \)), defined as the average adoption lag for each country for the four instrument drugs (Statins, PPIs, CCBs, ACE inhibitors) which are indexed by \( d \). In Eq. (4) \( \text{launch}_d \) equals the year in which drug \( d \) was first sold (or “launched”) anywhere in the world, and \( \text{launch}_d \) is the year drug \( d \) was launched in country \( i \) specifically.

\[ P_{Lag} = \text{int} \left( \sum_{d} \frac{\text{launch}_d - \text{launch}_d}{4} \right) \quad (4) \]

27 We were only able to obtain sales data for these drugs back to 1994, and so linearly interpolate annual sales data for countries for the years between when the country first approved the drug for sale and 1994 (in cases where countries approved before 1994).

28 The fifth class is antihistamines.
Then for each country and calendar year, we calculate the number of years we predict SSRI would have been on the market if the SSRI adoption lag for that country was the same as the average adoption lag observed for the four instrument drugs. That is, Predicted_Year_ad equals the year in which SSRIs were first sold anywhere in the world (launch SSRI) plus the country’s average adoption lag for the four instrument drugs (P_Lag). For example, the U.S. approved Statins, PPIs, CCBs and ACE inhibitors on average one year after they were introduced anywhere on the world market. Since SSRIs were first launched on the world market in 1984, for the U.S., Predicted_Year_ad = 1 in 1985 (a bit earlier than when SSRIs were actually first sold in America, 1988), Predicted_Year_ad = 2 in 1986, and so on for each of the k years SSRIs would have been for sale in each country. Then for the kth year we predict SSRIs to have been on the market in a given country, our instrument, PSALES_{it}, equal the average sales rate per capita of Statins, PPIs, CCBs, and ACE inhibitors the kth year these drugs were on the market in country i. So for the U.S., when Predicted_Year_ad = 1 in 1985, PSALES_{it} equals the average sales per capita of Statins, PPIs, CCBs and ACE inhibitors in their first years on the U.S. market. In 1986, Predicted_Year_ad = 2 and PSALES_{it} is the average sales of our four instrument drugs the second year they were on the U.S. market. So, starting in the first predicted year, our instrument is:

$$PSALES_{it} = \frac{1}{d} \sum_{k} Sales_{itk} \times 1(\text{Predicted}_\text{Year}_{ad} = k)$$  (5)

One limitation of our just-identified IV setup is that the first-stage model imposes the assumption that each 1-unit increase in sales of our other instrument drugs always has the same effect on SSRI sales, regardless of how long these drugs have been on the market. But from Table 1 it is clear that SSRI sales growth was initially quite slow, which was not typical of the other drugs we use to construct our instrument. For this reason, we also estimate a model that allows the relationship between sales of other drugs and sales of SSRIs to vary with time these drugs are on the market, by creating a separate instrument equal to general drug sales the kth year these drugs are on the market and allowing the coefficients to vary. In this more flexible first-stage specification, we predict SSRI sales in the kth year for each country as:

$$PSALES_{itk} = \frac{1}{d} \sum_{d} Sales_{itk} \times 1(\text{Predicted}_\text{Year}_{it} = k)$$  (6)

We then estimate the following system, exploiting k separate instruments to identify the effects of SSRI growth within countries on changes in suicide rates:

$$Y_{it} = b_0 + b_1SSRI_{it} + b_2X_{it} + d_1 + d_1 \times Time \times d_1 + v_{2it}$$  (7)

$$SSRI_{it} = c_0 + \sum_{k} \delta_k PSALES_{itk} + c_2 X_{it} + d_1 + d_1 \times Time \times d_1 + v_{3it}$$  (8)

If there is heterogeneity in how people’s risk of suicide responds to SSRI treatment, then our IV estimates will (if our instruments are valid) capture the effect of SSRI sales increases on those people whose SSRI use at each point in time is affected by institutional factors that influence drug regulation, distribution and demand systems across countries and are picked up by our instruments. As new drugs generally diffuse through the population, some people begin to use the drug (that is, move from zero to non-zero dosage level), while other patients are induced to increase their usage level of the drug. We assume that people in countries where new drugs in general diffuse more quickly do not become less likely to take up SSRI treatment or increase their SSRI dosage (this is the standard monotonicity assumption). In that case our IV estimates should reflect the average of the causal responses to incremental increases in SSRI use among those people enticed to increase their SSRI use by whatever causes drugs in general to diffuse more rapidly across different countries. This is the “average causal response” (or ACR) from Angrist and Imbens (1995). Our IV estimates cannot be interpreted as the average effect of SSRI treatment on all people, or even the average effect of SSRI treatment on those who get treated. Different policy or clinical mechanisms that push different types of people into SSRI treatment could generate different treatment responses from those that are estimated here. Yet to the extent to which policy influences the institutional factors that determine the rate at which new drugs diffuse generally, then our IV estimates should be of interest to health policy analysts and policymakers.

6. Findings

As a point of departure, consider the time series of log suicide rates and SSRI sales per capita for the OECD countries in our sample from 1980 to 2000 (Fig. 1). Consistent with the hypothesis that SSRIs may reduce suicide we find a decline in suicide mortality in this sample of countries starting in the mid-1990s, about when SSRI sales increase dramatically. However this is less than definitive proof, given the data show some changes in suicide before SSRIs were on the market. Our preferred IV estimates suggest that an increase in SSRI sales of 1 pill per capita reduces suicide mortality by around 5%—about twice as large as OLS estimates. This relationship is largest in absolute value among relatively younger people.

---

29 If our explanatory variable of interest was binary then we would think about our IV estimates as a local average treatment effect. If there were no “always takers” or no “never takers” we could learn about the average effect on the treated (or on the not treated). But we see in our data that there are countries with positive SSRI sales values even before our instruments predict other new drugs would have begun diffusing, and there are countries where SSRI sales are zero even during periods when other drugs in general would have rapidly diffused throughout the population.

30 The increase in the early 1980s observed in Fig. 1 is probably driven by changes in suicide in several countries during a period of economic recession. Another contributing factor is the increase in suicide rates in Mexico from extremely low initial levels up closer to international norms, which might reflect some declining stigma of suicide in that predominantly Catholic country.
Table 3

<table>
<thead>
<tr>
<th>Population age distribution</th>
<th>Outcome measure = log(suicides/100,000)</th>
<th>Outcome measure = log(suicides/100,000)</th>
<th>Outcome measure = log(suicides/100,000)</th>
<th>Outcome measure = log(suicides/100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Population 15–24</td>
<td>-.0350 (.0074)</td>
<td>-.0258 (.0011)</td>
<td>-.0198 (.0102)</td>
<td>-.0204 (.0094)</td>
</tr>
<tr>
<td>% Population 25–34</td>
<td>.0305 (.0254)</td>
<td>.0007 (.0221)</td>
<td>.0006 (.0201)</td>
<td>.0218 (.0201)</td>
</tr>
<tr>
<td>% Population 35–44</td>
<td>.0297 (.0187)</td>
<td>.0275 (.0224)</td>
<td>.0159 (.0218)</td>
<td>.0159 (.0218)</td>
</tr>
<tr>
<td>% Population 45–54</td>
<td>.0287 (.0143)</td>
<td>.0087 (.0212)</td>
<td>.0268 (.0254)</td>
<td>.0268 (.0254)</td>
</tr>
<tr>
<td>% Population 55–64</td>
<td>.0025 (.0291)</td>
<td>-.0298 (.0251)</td>
<td>.0139 (.0237)</td>
<td>.0139 (.0237)</td>
</tr>
<tr>
<td>% Population 65 and over</td>
<td>.0059 (.0214)</td>
<td>.0130 (.0259)</td>
<td>.0268 (.0254)</td>
<td>.0268 (.0254)</td>
</tr>
<tr>
<td>ICD-10 system used to classify mortality codes</td>
<td>-.0079 (.0422)</td>
<td>-.0417 (.0252)</td>
<td>-.0279 (.0238)</td>
<td>-.0279 (.0238)</td>
</tr>
</tbody>
</table>

Indicators for years before SSRIs on the market:

- 1 year before: -.0309 (.0194)
- 2 years before: -.0625 (.0416)
- 3 years before: -.0994 (.0410)
- 4 years before: -.0867 (.0353)
- 5 years before: -.0867 (.0353)

Model specification

- Year indicators: Yes
- Country indicators: Yes
- Country-specific linear trends: No
- N: 541
- R^2: .977

Notes: Table reports least squares regression coefficients. Standard errors in parentheses. Regression models also include a constant intercept term. Country populations used as weights. For more details on estimation approach see text.

1. p < .10
2. p < .05

6.1. OLS results

Table 3 shows countries that experienced relatively larger increases in SSRI sales over our study period also experienced relatively larger declines in suicide. When we regress log suicide rates against SSRI sales and country and year fixed effects (column 1), an increase in sales of 1 pill per capita (about 12% of the mean 2000 sales levels in our sample) is associated with a reduction in suicide of around 3.5%. As best we can tell, the increase in SSRI sales in our data comes from about equally large changes along the extensive margin (number of patients treated) and intensive margin (pills per patient, which could be due in part to increased patient treatment fidelity because of fewer physical side effects of SSRIs versus TCAs). 32

Fig. 2 provides some additional intuition about this estimate by plotting for each country the change in log suicide rates from 1980–1995 against the change in SSRI sales. 33 Fig. 2 helps illustrate the substantial variation in the growth of SSRI sales across countries. For example SSRI sales increased about twice as much in the US as in the UK, while by 1995 Japan had not even introduced SSRIs for sale yet. Of course countries may experience different trajectories in suicide rates for a variety of reasons other than SSRI sales. The second column of Table 3 shows that controlling for population age structure reduces the magnitude of the point estimate by around one-third. Adding country-specific linear trends (column 3) has only a modest impact on the magnitude of our point estimate. This estimate (2% suicide reduction per pill per capita) is of about the same magnitude as in Ludwig and Marcotte (2005), though the sample of countries is different. An alternative to our strategy of treating the country intercepts as fixed would be to treat the intercept and slopes of the country-level trends as random effects. When we do this our estimates are very similar. Treating the country-level intercept and slopes as random effects, we estimate that suicide rates fall by 2.5% per pill per capita using a Poisson model, and 2.1% using a standard mixed effects model.

The main concern with these OLS estimates is that SSRI sales may be endogenous to the conditions that influence suicide. For example there is much more variation across countries in how quickly they approve SSRIs for public sale compared to how quickly these countries approve other drugs: Of the 26 countries in our panel, 23 approved the four major non-psychiatric drugs that we use as instruments (from Table 2, Statins, PPIs, CCBs, and ACE inhibitors) within the first 3 years that these drugs came on the world market. In contrast, only 6 of our 26 countries approved SSRIs for sale within the first 3 years that these drugs first came on the market in 1984. 34 The extra variability in the timing of SSRI approval

---

32 Ludwig and Marcotte (2005, Fig. 4) show that in the U.S., the number of TCA prescriptions held steady from the late 1980s through the late 1990s at around 30 million prescriptions per year. Paulose-Ram et al. (2007) suggest that the proportion of people 17 and older receiving psychotropic treatment for depression increased from 2.5% in 1988–1994 to 8.1% in 1999–2002, which would suggest an increase from 4.9 to 17.9 million people receiving treatment. Our IMS data suggest the number of SSRI sales in the mid-points of the two periods studied by Paulose-Ram et al. went from around 215 million doses to 4.2 billion doses. If we assume around 20 doses per prescription for TCAs (about the number implied by our data on SSRI doses and SSRI prescriptions from Ludwig and Marcotte’s Fig. 4), then there were around 815 million doses of anti-depressant drugs sold to around 4.9 million people in the 1988–1994 period, or about 166 doses per patient per year. In 1999–2002 there were (assuming TCA doses held constant) 4.8 billion doses sold to 17.9 million people, or about 268 doses per patient. These calculations imply that roughly half of the increase in SSRI sales sold of 4 billion from 1988–1994 to 1999–2002 came from an increase in the number of people receiving treatment, the other half from an increase in the number of doses per patient.

33 Even though we have suicide and SSRI sales data through at least 1999 for all of the countries in our sample, with our IV design described below we lose some country-years’ data after 1995, and so for consistency in these figures we focus here on the 1980–1995 period. Re-doing Fig. 2 using data through 1999 yields a similar picture.

34 SSRIs were first sold anywhere in the world in West Germany in 1984, which is dropped from our sample as described in Section 3 because of the effects of reuni-
compared to other drugs suggests regulators in some countries may have had special concerns about the SSRIs, or that demand for mental health services are more variable across countries than demand for other medical services.

In fact we find some evidence suggesting that countries with increasing suicide rates may have been quicker to approve SSRIs for public use, as shown in the fourth column of Table 3. We estimate our basic panel-data setup as in Eq. (1) but now add a set of indicator variables for each of the five years before SSRIs were first sold in each country. We find these pre-SSRI year indicators are jointly significant ($p < .01$) and become less negative (smaller in absolute value) as we get closer to the time SSRIs were approved. 

It is more difficult to generate a similarly transparent test for the endogeneity of SSRIs sales growth once these drugs are on the market, though there is ample reason to be worried about simultaneity with trends in SSRI sales and mental health conditions. These conceptual concerns, together with the empirical findings above, motivate the IV analysis that follows.

6.2. Main IV results

The first column of Table 4 shows the first-stage results from estimating our just-identified IV model. Each one-pill increase in predicted sales for our four other instrument drug set is associated with higher levels of SSRI sales equal to around two-fifths of a pill per capita. The F-statistic on our instrument is equal to 21.2 ($p = .0001$). The second column shows our second-stage estimate: Each one-pill increase in predicted SSRI sales is associated with a decline in suicide rates of around 8.5% ($p < .05$).

As noted above, a limitation of our just-identified setup is that it assumes that a given unit change in sales of our instrument drugs has the same effect on SSRI sales regardless of where we are in the lifecycle of the drug. The IV design with interacted instruments allows the coefficient on our predicted SSRI sales level to vary by the number of years SSRRs are predicted to have been on the market in a country. The third column of Table 4 shows our first-stage results with this set of interacted instruments, which compared to the just-identified first-stage in column (1) increases our first-stage F-test statistic by more than one-third (29.2 versus 21.2). Given that we have a relatively large number of instruments (15) the concentration parameter may be a better indicator for first-stage explanatory power (Hansen et al., 2005), which is equal to $15 \times (F - 1) = 422.9$.

The final column of Table 4 shows that the estimates from our multiple-instrument second-stage equation suggest that an increase of 1 SSRI pill per capita reduces suicide rates by around 5% ($p < .05$). This estimate is smaller than our just-identified result, but from here forward we use this interacted-instrument setup as our preferred model given the relatively greater first-stage power and (as shown below) greater robustness to a wide range of sample restrictions and other sensitivity tests.

Our preferred IV estimate in column (4) of Table 4 is about twice as large as the OLS estimates in Table 3, consistent with the idea that variation in actual SSRI sales may be driven in part by trends within these countries in suicide mortality or negative mental health conditions generally, although a standard Hausman test (1978) shown in the last row of the table does not quite allow us to reject the null hypothesis that our OLS and IV estimates are equal ($p = .11$).

For purposes of interpretation, a one pill per capita increase in SSRI sales represents about a 12% increase over the average 2000 sales level across our sample of countries. An increase of one pill per capita also represents a 41% increase in average sales over our entire sample period, so that the estimated elasticity of suicide with respect to SSRI sales implied by the results in Table 4 is equal to around −12. Our IV estimates also seem generally consistent with the sort of effect on suicide mortality we would predict based on the RCT evidence for how SSRRs impact depression, together with the epidemiological literature on how depressive disorder elevates the risk for suicide completion, although we note these calculations themselves are subject to some uncertainty.

---

36 Hahn and Hausman (2002) suggest an alternative test for weak instruments that we have also conducted. If the instruments are weak under this test, LIML might be preferred, but our test results suggest with our instruments that 2SLS should be fine. Hansen’s test of over-identifying restrictions in this model yields a $p$-value of 495, although interpretation of this type of test statistic is in general complicated if there is treatment heterogeneity.

37 When we replicate our IV estimates and include indicator variables for each of the five years before we predict SSRIs to first be sold in each country, we find these indicators are not statistically significant. But this is a weak test because there is little variation across countries in when SSRIs would first be sold if adoption lags for SSRIs were similar to those for our instrument drugs.

38 Note that not all of the relevant data we would want for calculating the suicide mortality impact we would expect from the effect of SSRIs on depression and the link between depression and suicide are available, and so this calculation requires a number of assumptions. As noted in an earlier footnote, we estimate that in the 1999–2002 period, the typical patient receiving psychotropic drug treatment for depression received around 268 doses per year, so that an additional 1 pill per capita increase in SSRI sales in the US multiplied by a population of 270 million implies around 270 million additional doses, or roughly 1 million more people receiving anti-depressant drug treatment. The recent IOM report on suicide suggests that between 30 and 90% of suicide decedents suffered from depression; we assume a mid-point figure, of 60%, or around 18,000 of the 30,000 suicide decedents in the US each year. These figures imply a suicide mortality rate of 128 per 100,000 for those with depression versus around 6 per 100,000 for those without depression. Using Kessler et al.’s (2003) estimate of 14 million American adults suffering from major depressive disorder in a given year (and so 195 million Americans without depression), Bech et al.’s meta analysis (2000) finds that SSRIs treatment reduces the probability of depressive symptoms by 55%. But, placebo reduces the probability by fully 35%. The placebo effect in treatment of major depressive disorder is large, and its interpretation remains contentious (Stolk et al., 2003; Miller, 2003; Walsh et al., 2002). It is not clear whether the placebo effect is part of the therapeutic
Table 4
First- and second-stage instrumental variables estimates.

<table>
<thead>
<tr>
<th></th>
<th>Outcome measure = SSRI sales per capita</th>
<th>Outcome measure = log (suicides/100,000)</th>
<th>Outcome measure = SSRI sales per capita</th>
<th>Outcome measure = log (suicides/100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSRI doses sold per capita</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Instrument: predicted drug sales</td>
<td>.3879 (.0842)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Instruments: predicted drug sales by year since predicted approval date</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Population 15–24</td>
<td>.2506 (.1148)*</td>
<td>.0069 (.088)</td>
<td>.1867 (.1233)</td>
<td>.0010 (.0196)</td>
</tr>
<tr>
<td>% Population 25–34</td>
<td>-.6177 (.1834)*</td>
<td>-.0334 (.0366)</td>
<td>-.5099 (.1693)</td>
<td>-.0111 (.0280)</td>
</tr>
<tr>
<td>% Population 35–44</td>
<td>-.2963 (.2774)</td>
<td>-.0017 (.0327)</td>
<td>-.2821 (.2909)</td>
<td>.0199 (.0347)</td>
</tr>
<tr>
<td>% Population 45–54</td>
<td>.0427 (.3063)</td>
<td>.0030 (.0343)</td>
<td>.0729 (.2487)</td>
<td>-.0264 (.0282)</td>
</tr>
<tr>
<td>% Population 55–64</td>
<td>-.1596 (.2867)</td>
<td>.0547 (.0347)</td>
<td>-.1292 (.2786)</td>
<td>.0524 (.0361)</td>
</tr>
<tr>
<td>% Population 65 +</td>
<td>-.2122 (.3999)</td>
<td>-.0038 (.0479)</td>
<td>-.2096 (.3346)</td>
<td>-.0307 (.0391)</td>
</tr>
<tr>
<td>ICD-10 system to code mortality causes</td>
<td>-.2763 (.2954)</td>
<td>.0250 (.0473)</td>
<td>-.15687 (.7415)</td>
<td>.0412 (.0549)</td>
</tr>
</tbody>
</table>

Model specification

| Year indicators?          | Yes | Yes | Yes | Yes |
| Country indicators?       | Yes | Yes | Yes | Yes |
| Country-specific linear trends? | Yes | Yes | Yes | Yes |

F-test on joint significance of instruments in first stage

| F-test                  | 21.24 (p < .0001) |
| N                      | 428 |
| R²                     | .985 |

Hausman test of endogeneity of SSRI sales (t-statistic)

<table>
<thead>
<tr>
<th>t-statistic</th>
<th>1.96 (p = .05)</th>
</tr>
</thead>
</table>

Notes: Table reports least squares regression coefficients. Standard errors in parentheses. Country populations used as weights. For more details on estimation approach see text.

* p < .10.
* * p < .05.

6.3. Robustness checks

Our results seem generally robust to alternative model specifications and changes in our analytic sample. For example, our findings are not driven by the experiences of just a few outlier countries.

This is easiest to see from a visual inspection of the difference-in-difference analog to our preferred IV estimates (Fig. 3). The horizontal axis shows the change in the predicted value of SSRI sales from 1980 to 1995 for each country from Eq. (4) above, while the vertical axis shows the simple change in log suicide rates over the same period. The simple bi-variante relationship between change in log suicide rates and change in predicted SSRI sales is negative, consistent with the results of our preferred IV analysis; visual inspection suggests the estimate does not appear to be driven by the experiences of outlier countries. More formally in Table 5 we re-estimate our IV model excluding different countries. First, we drop countries that Fig. 3 suggests might exert special leverage over the regression line (U.S., Mexico, and Japan) and obtain similar results. The second column of Table 5 shows qualitatively similar results hold when we restrict the analytic sample just to member nations of the OECD in our sample. We also obtain comparable results when we drop countries with populations smaller than 5 million (Ireland, Israel, Luxembourg, New Zealand, and Norway).

The remainder of Table 5 shows the results are qualitatively similar under a variety of other changes in our estimation approach, including dropping country-year observations in the late 1980s when SSRI sales were imputed, or excluding our controls for population age structure and ICD-10 coding. We also obtain similar
Table 5
Sensitivity analyses.

<table>
<thead>
<tr>
<th>Model specification</th>
<th>Full sample</th>
<th>OECD countries only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline specification</td>
<td>−0.0542 (0.0190)</td>
<td>−0.0499 (0.0178)</td>
</tr>
<tr>
<td>Drop US</td>
<td>−0.0975 (0.0383)</td>
<td>−0.0665 (0.0252)</td>
</tr>
<tr>
<td>Drop Mexico</td>
<td>−0.0745 (0.0238)</td>
<td>−0.0770 (0.0227)</td>
</tr>
<tr>
<td>Drop US and Mexico</td>
<td>−0.1475 (0.0473)</td>
<td>−0.0917 (0.0580)</td>
</tr>
<tr>
<td>Drop Japan and Mexico</td>
<td>−0.0601 (0.0190)</td>
<td>0.0191 (0.0184)</td>
</tr>
<tr>
<td>Drop small countriesa</td>
<td>−0.0467 (0.0194)</td>
<td>0.0368 (0.0226)</td>
</tr>
<tr>
<td>Drop obs with imputed sales</td>
<td>−0.0503 (0.0164)</td>
<td>0.0496 (0.0170)</td>
</tr>
<tr>
<td>No time-varying covariates</td>
<td>−0.0408 (0.0161)</td>
<td>0.0319 (0.0112)</td>
</tr>
<tr>
<td>Control for divorce rate</td>
<td>−0.0470 (0.0144)</td>
<td>0.0435 (0.0145)</td>
</tr>
<tr>
<td>Control for unemployment rate</td>
<td>−0.0509 (0.0191)</td>
<td>0.0521 (0.0182)</td>
</tr>
<tr>
<td>Control for real per capita GDPb</td>
<td>−0.0513 (0.0173)</td>
<td>0.0318 (0.0171)</td>
</tr>
<tr>
<td>Control for unemployment and real per capita GDPc</td>
<td>−0.0515 (0.0167)</td>
<td>0.0353 (0.0177)</td>
</tr>
<tr>
<td>Control for country total population</td>
<td>−0.0489 (0.0190)</td>
<td>0.0436 (0.0214)</td>
</tr>
<tr>
<td>Restrict sample to ≤ 1997</td>
<td>−0.0464 (0.0173)</td>
<td>0.0353 (0.0210)</td>
</tr>
<tr>
<td>Un-weighted</td>
<td>−0.0442 (0.0269)</td>
<td>0.0307 (0.0273)</td>
</tr>
<tr>
<td>Not logged</td>
<td>−2.404 (2.070)</td>
<td>2.973 (3.001)</td>
</tr>
</tbody>
</table>

Notes: Each cell includes the coefficient for predicted SSRI sales values by applying the basic IV estimation approach as in Table 4 to the analytic sample described at the top of the column, with deviations from the basic model setup described at left for each row. Robust standard errors are in parentheses, clustered at the country level to account for serial correlation.

* Small countries are those with average population under 5 million. These are Ireland, Israel, Luxembourg, Norway and New Zealand.

b Figures for real per capita GDP adjusted for exchange rate variation over time.

p < .1

p < .05

country population, the un-weighted point estimate is similar although somewhat less precisely estimated. Re-calculating the estimates using actual rather than logged suicide rates yields a point estimate of −.24, which given an average suicide rate of 10.2 in our panel (Table 1) implies that an increase in SSRI sales of 1 pill per capita reduces suicide by around −2.5%, about half the size of the log specification and now no longer statistically significant. However given the substantial differences in suicide levels across countries described above a log-linear model that estimates SSRI impacts in proportional rather than absolute terms seems preferable.

Implicit in our IV design is the notion that there is some “usual” way that new drugs are approved and sold within a country. Consistent with this assumption we find that the adoption lags across the OECD countries in our sample for our four instrument drugs are all highly correlated (between +.8 and +.9). If we regress actual sales values for our instrument drugs against one another using our panel of country-level data the R-squared values are usually on the order of .5–6.40 In calculating our baseline IV first stage, we essentially weight each of our four instrument drugs in proportion to their relative sales levels and growth rates. This specification gives somewhat more weight in the calculation of our instrument to ACEs and CCBs (with mean sales levels over our study period of 22 and 17 pills per capita, respectively, and standard deviations of around 10 or 11 pills per capita) than to Statins and PPIs (with mean sales of around 8 and 6 pills per capita, and standard deviations of 7 and 5). When we instead normalize each of our instrument drugs (subtracting from each country-year observation for each of our instrument drugs the sample mean sales level then dividing by

40 Another way to see this is by constructing new versions of our instruments that use separately each of the four instrument drugs (Statins, CCBs, ACE inhibitors and PPIs). In our full sample the estimates using Statins, ACE inhibitors, and PPIs range from −.03 to −.045, close to our preferred IV estimate of −.05. The outlier comes from using CCBs alone to construct our instruments, which seems to be driven in part by the fact that CCBs were a smash success in Japan, with CCB sales levels that are much higher than in any other country (and also much higher than those of our other drugs in Japan for that matter). CCB sales will thus have more limited power to explain growth in SSRI sales because Japan has unusually high CCB sales but unusually low SSRI sales (given its late adopter status). When we restrict our sample to just OECD countries, the Japan effect in distorting the first stage with the CCB instruments is even more pronounced.

results when we add controls for a variety of risk factors that have been shown to be associated with suicide (Goldsmith et al., 2002), including each country’s divorce rate and measures of economic conditions or hardship such as unemployment rate and real GDP per capita. Our estimates are not simply picking up the effects of population growth over time within our countries, as can be seen by the fact that controlling for each country’s total population in each year has little effect on our point estimates or standard errors.

Our panel is a bit unbalanced because the amount of data available on our instrument drugs varies a bit across years, but replicating our analysis on a balanced panel using data just through 1997 yields similar results. While our main estimates weight by

---

Fig. 3. IV Model–change log suicide rates, 1980–1995 versus predicted change SSRI sales.
the standard deviation), our second-stage IV point estimate is very close to the results from our baseline specification. This pattern is consistent with the idea that our instrument drugs are tapping into some common pattern of new drug sales differences across countries.

6.4. Additional specification tests

The main threat to our study is the possibility that the our instruments – the rate at which new drugs generally diffuse within each country – may not be orthogonal to other determinants of suicide, such as the quality or quantity of health care, or that drug diffusion itself may directly influence suicide mortality by affecting physical health conditions or the amount of pain treatment for chronically ill people, or other hard-to-measure variables such as the prevalence of psychotherapy use. In this section we provide several empirical tests that try to rule out these alternative explanations.

One obvious concern is the possibility that new drugs diffuse more rapidly in countries that spend more on health care. In this case, we may attribute reductions in suicide to SSRI use rather than to underlying changes in the sorts of chronic physical health problems that may lead people to contemplate suicide. We address this concern by utilizing data on health care expenditures per capita that we can obtain for a sub-set of our analytic sample, most of which are OECD member nations. It turns out that countries where drug sales increase more rapidly (and so are predicted to have higher rates of SSR1 growth) do not seem so atypical with respect to growth in overall health spending. Fig. 4 shows that when we divide the countries for which we have health spending data into three categories – those that are predicted to have high levels of SSRI growth on the basis of our instruments (<7 SSRI doses per capita), medium levels of growth (4–7 doses), and low levels of growth (<4 doses) – we see similar trends in health expenditures over the period 1980–2000. When we re-estimate our IV model using just the sub-set of countries for which we have health spending data, adding the health expenditure variable as a control has hardly any impact on our IV estimate for the effect of SSRI sales on suicide (−.071 with versus −0.075 without, statistically significant in both cases).

A different test for whether our instruments may simply be picking up the effectiveness of the overall health care system comes from re-estimating our IV model for a different cause of death that should not be causally affected by SSRI treatment. This sort of falsification test would be most informative if we focus on causes of death that should also not be substantially affected by drug treatments of any type, since our basic IV design comes from comparing countries with relatively high and low rates of growth in new drugs more generally. One natural candidate is accidents. The estimated coefficient for the “effect” of SSRI sales on the log of accident mortality rates is equal to −.0108 (SE = 0.0269), which is not statistically significant and about one-fifth as large as the estimated effect of SSRIs on suicide.

Even if our instruments are not systematically related to the structure or resources of a country’s overall health care system, it is logically possible that our instruments could potentially have a direct effect on suicide mortality by affecting physical health. That is, in countries where new drugs diffuse more rapidly, it could be that drug therapy does more to reduce the sorts of chronic health problems that lead some people to consider suicide, or that pain treatment for such cases is more intensive. This hypothesis would predict that in countries where we predict more rapid SSRI sales growth – that is, where new drugs generally diffuse more rapidly – suicide mortality reductions should be concentrated among older people, since the prevalence of most of the serious physical health problems increase with age.41

To test this prediction we can re-estimate our preferred IV specification, but now replacing the dependent variable measure of overall suicide mortality with age-specific suicide mortality rates. This is not a very good test for age heterogeneity in treatment response to SSRIs, since we do not have data from IMS Health on SSRI sales for separate age groups. Data from countries where data on SSRI sales by age are available – the U.S., Australia, and Canada – suggest that over the course of the 1990s SSRI use increased the most in proportional terms among younger people, although we would not make too much of this fact since these three countries represent just a small sub-set of our total analytic sample.42 But in any case, examining how changes in overall SSRI sales affect suicide mortality to different age groups does provide some power to rule out the specific counter-factual explanation that our results may be due to the instruments’ effects on physical health or pain control. Yet as Table 6 shows, we find that the estimated relationship between SSRI sales and suicide mortality is largest in both proportional and absolute terms for people ages 15–24. The only other group for which we find a significant relationship is for those between the ages 25–34.43 This pattern is not consistent with a “physical health” channel. However this pattern of results is consistent with the idea that relatively younger people are the ones who are most likely to become depressed and consider suicide in response to adverse, but temporary, changes in their life conditions (Goldsmith et al., 2002), and so may benefit the most from depression treatment that helps them weather these difficult spells. Survey data from the U.S.

41 For example, results of the National Health and Nutrition Examination Survey in the U.S. indicate that prevalence of hypertension and high levels of serum cholesterol – conditions treated by three of our four instrument drugs – rise substantially with age (http://www.cdc.gov/nchs/about/major/nhanes/datablelink.htm, Tables 67 and 68, accessed December 7, 2007.)

42 For example, in the U.S., between 1988 and 2002 the proportion of adults in the U.S. prescribed antidepressants increased from 2.5% to 8.1% (Paudose-Ram et al., 2007). Between 1987 and 1996 the increase in the rate of prescriptions to children and adolescents ranged from four to ten fold in different Medicaid and HMO claims files (Zito et al., 2003). By 1996, Zito et al. estimate that about 2% of children and adolescents were being treated with antidepressants. In Australia, between 1990 and 2001 the use of antidepressants among 15–24 year olds increased by 10-fold, from 1.2 defined daily doses (DDD) per 1000 people per day to 14.3 for males, and from 3.2 to 30.7 for females. This compares to an increase of four-fold for 45–54 year olds, from 10.9 to 43.4 for males and 22.4–86.7 for females (Hall et al., 2003). In Canada, the percent of persons with major depression treated with antidepressants increased between 1994 and 2001 from 6.8 to 30.6 for 15–34 year olds, compared to 21.0 to 31.3 for 35–54 year olds (Patten and Beck, 2004).

43 We also find that the IV point estimates are larger in proportional terms for females than males, although since the baseline suicide mortality rate in our data about three times as high for males as for females (Table 1) the estimated association between SSRIs and suicide in absolute terms (deaths per 100,000) will be somewhat larger for males than females.
show the lifetime prevalence of major depression disorder is much higher than the 12-month prevalence, 16.6 versus 6.6% (Kessler et al., 2003); depression for some people is a temporary rather than permanent condition.

One final and quite general test of our identification strategy comes from examining whether the countries that our research design predicts should have more rapid versus less rapid growth in SSRI sales over time have similar trends in suicide mortality rates before SSRIs come on the market. The top panel of Fig. 5 shows there is almost no relationship between the predicted growth in SSRI sales for our countries during the period 1988–1995, when SSRI use became common, with the rate of change in log suicide rates during the previous period from 1980–1988 (the slope of the regression line is equal to \(+0.005 \)). In contrast, there is a pronounced negative relationship between the change in log suicide rates from 1988–1995 with the predicted change in SSRI sales over this same period (the slope is \(-0.22)\).

For a subset of our countries we can obtain suicide mortality data going back to 1960, and here again we see evidence of quite similar “pre-treatment” trends in suicide. We divide these countries into three groups based on the predicted growth rate of SSRI sales from our IV design. Fig. 6 shows that suicide rates showed a similar upward trend from about the mid-1960s through the late 1980s in countries with high, medium, and low predicted growth rates in SSRI sales. This steady upward trend in suicide mortality persists through the year 2000 in countries with low or medium predicted rates of SSRI sales, but shows a clear break in trend for the high-SSRI-growth group starting in the very late 1980s—just as SSRI sales start to take off (see for example Fig. 1). As a way to think about the magnitudes of the dose–response relationship suggested by Fig. 6, within our set of predicted “high growth” countries actual SSRI sales equaled around 500,000 pills total in 1986, which increased to around 5 million in 1987, then to 61 million in 1988 and 134 million in 1989. Over this period the total number of completed suicides in this set of countries declined by around 300 per year each year from 1986 to 1988, and then by nearly 900 from 1988 to 1989.

We have established that countries with different predicted growth rates in SSRI sales have similar suicide trends before SSRI use became prevalent, that trends in suicide mortality only differ across these countries in the period when SSRI sales increased sub-

---

**Table 6**

IV results for the estimated effect of SSRI sales on suicide mortality for population sub-groups.

<table>
<thead>
<tr>
<th>Dependent variable</th>
<th>Full sample</th>
<th>OECD countries only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log suicide, age 15–24</td>
<td>–0.0578 (.0275)*</td>
<td>–0.0849 (.0558)</td>
</tr>
<tr>
<td>Log suicide, age 25–34</td>
<td>–0.0525 (.0226)**</td>
<td>–0.0326 (.0341)</td>
</tr>
<tr>
<td>Log suicide, age 35–44</td>
<td>.0000 (.0303)</td>
<td>.0223 (.0306)</td>
</tr>
<tr>
<td>Log suicide, age 45–54</td>
<td>–0.0171 (.0305)</td>
<td>–0.0249 (.0251)</td>
</tr>
<tr>
<td>Log suicide, age 55–64</td>
<td>–0.0398 (.0318)</td>
<td>–0.0228 (.0317)</td>
</tr>
<tr>
<td>Log suicide, age 65+</td>
<td>–0.0253 (.0394)</td>
<td>–0.0145 (.0335)</td>
</tr>
<tr>
<td>Log suicide, females</td>
<td>–0.0775 (.0174)**</td>
<td>–0.0973 (.0184)**</td>
</tr>
<tr>
<td>Log suicide, males</td>
<td>–0.0539 (.0215)**</td>
<td>–0.0483 (.0214)**</td>
</tr>
</tbody>
</table>

**Notes:** Each cell includes the coefficient for predicted SSRI sales values by applying the basic IV estimation approach as in Table 4 to the analytic sample described at the top of the column, with the dependent variable of interest described at left for each row. Robust standard errors are in parentheses, clustered at the country level to account for serial correlation.

---

**Fig. 6. Suicide rates in countries with Low, Medium, and High rates of predicted SSRI sales growth.**

---


---

**Fig. 6. Suicide rates in countries with Low, Medium, and High rates of predicted SSRI sales growth.**
Fig. 7. Global sales of SSRIs vs. all other anti-depressants.

Our estimates also do not appear to be influenced by the introduction in the mid to late 1990s of another class of anti-depressants, the serotonin–norepinephrine reuptake inhibitors, since sales of SNRIs did not really take off until the late 1990s (Fig. 7) and Table 5 shows our results are unaffected by using data only through 1997.47

7. Conclusions

Understanding the effects of SSRI anti-depressants on suicide is important for regulators, doctors, patients, and the family and friends of those suffering from severe depression. It is unlikely that randomized clinical trials (RCTs) will ever be able to identify the effects of SSRIs on suicide mortality, both because of small samples and because these samples exclude those at highest risk for suicide. Previous clinical trials instead focus on measures of non-lethal “suicidal behavior,” but the association between these indicators and actual suicide mortality remains unclear. Moreover the conditions under which subjects in RCTs use SSRI drugs (for example level of physician monitoring) may differ from the usual community standard of care.

In light of these practical and ethical constraints, we must turn to population-based observational studies to adequately identify the effects of SSRIs on suicide completion rates. We believe our study represents a substantial improvement over previous research by using population-level data together with a plausibly exogenous source of identifying variation in SSRI use. Specifically we use just the variation in SSRI sales across countries over time that can be explained by how quickly these countries adopt new drugs in general, and the rate at which sales increase for these new drugs once they are on the market.

Our results are consistent with the hypothesis that the net effect of the introduction and subsequent sales of SSRIS is to reduce death by suicide. We find that increase in SSRI sales of 1 pill per capita per year (about a 12% increase over 2000 sales levels) is associated with a decline in suicide mortality of around 5%. This IV estimate is about twice as large in absolute value as OLS estimates, consistent with our concern that both the timing of SSRI approval and the rate of SSRI sales increases may be endogenous to mental health and suicide trends within countries. We also find no relationship between SSRI sales and accidental deaths, a type of mortality that should not be affected by SSRI use, and we find little relationship between trends in log suicide rates over the course of the 1980s and predicted SSRI sales growth in the 1990s.

If people’s suicide risks respond in different ways to SSRI treatment, then our IV estimates should capture the average effect of SSRI treatment on people for whom the receipt or intensity of their SSRI treatment is affected by whatever institutional factors cause new drugs to diffuse at different rates across countries more generally. These estimates do not reflect the average effect of SSRI treatment in the population overall or on those actually receiving SSRI treatment. But we believe our IV estimates are of interest since whatever institutional factors cause new drugs generally to diffuse...
at different rates across countries are likely to result from policy decisions about drug regulation, distribution and demand systems.

Our estimates suggest that at least among the set of people whose SSRI use is affected by our instrument, SSRIs may be a very cost-effective means for saving lives. Commonly used SSRIs can currently be obtained in the United States for around $0.11 per pill.48 Our estimates thus imply that each additional $22,000 spent on SSRIs will avert one suicide completion, far below the cost per life saved from most other public health, regulatory, or other forms of government intervention. But using this estimate in a more formal benefit–cost analysis raises difficult conceptual and normative questions about the appropriate way to value the life of someone who subjectively prefers death (at least at the time of the intervention), but another benefit of ‘demand reduction’ as a suicide prevention strategy is that it increases the subjective valuation of the depressed person’s life. Viscusi’s (2005) review of the literature on the statistical value of life puts the median estimate at $7 million for working age adults. Given the very low cost per life saved it is difficult to believe that expanding SSRI treatment would not pass a benefit–cost test, even if SSRI treatment is less effective than for the population for whom our IV estimates are relevant. This seems particularly likely to be true when we also consider that depression affects other outcomes such as parental functioning, human capital accumulation, employment, productivity, crime, child abuse, homelessness, and divorce (Frank and McGuire, 2000; Marcotte and Wilcox-Gök, 2001; Currie and Stabile, 2004).

Acknowledgments

The research reported here was supported by small grants to Marcotte and Ludwig from UMBC and the Georgetown University Graduate School of Arts and Sciences. Norberg was supported with funding from NIH grant SK08MH01809, and the Center for Health Policy at Washington University. None of the authors have received funding from pharmaceutical companies or other entities with financial interests relevant to the paper’s topic. Thanks to Josh Angrist, Jonathan Caulkins, Allison Cuellar, Philip Cook, Jeff DeSimone, William Dickens, Carlos Dobkin, Dan Feenberg, Ted Gayer, Jonathan Gruber, Jonathan Guryan, Chris Hansen, Brian Jacob, Jeffrey Kling, Alain Lesage, Byron Lutz, Sara Markowitz, James Mercy, Matthew Miller, Steve Pischke, Steve Raphael, David Salkever, Jesse Shapiro, Eric Slade, Betsey Stevenson, Justin Wolfer, seminar participants at the CDC, the NBER Children’s program and Health program, APPAM, and the University of Chicago, as well as the editor, Thomas McGuire, and two anonymous referees for helpful comments. We thank IMS Health, Inc. for their generosity in providing data on drug sales. Steve Hemelt, Özen Locman and Jake Ward provided excellent research assistance. Any errors and all opinions are of course our own.

References


